Article
Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation.
Cancer research - 1 Jul 2004
So Po-Lin, Lee Kenneth, Hebert Jennifer, Walker Patricia, Lu Ying, Hwang Jimmy, Kopelovich Levy, Athar Mohammed, Bickers David, Aszterbaum Michelle, Epstein Ervin H
Abstract excerpt
Oral retinoids can reduce basal cell carcinoma (BCC) incidence in genetically susceptible patients, and one topical retinoid, tazarotene, has been reported to cure some sporadic BCCs. Therefore, we have tested whether this agent would affect BCCs in Ptch1+/- mice in a controlled chemoprevention trial. We found that topical tazarotene dramatically inhibits the formation of BCCs induced with either UV or ionizing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
